THERAPEUTIC TARGETING OF ONCOGENES
Grant number: 1106576 | Funding period: 2016 - 2020
Treatments that target cancer causing genes called oncogenes have resulted in new treatment paradigms for cancer. We suggest that outcomes of patients with cancer will be further substantially improved by understanding how cancers can overcome resistance to these treatments that develops in many patients. To accelerate the adoption of these and other new treatments for cancer we will also develop new frameworks for clinical trials.
Related publications (6)
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma
Lorey K Smith, Tiffany Parmenter, Margarete Kleinschmidt, Eric P Kusnadi, Jian Kang, Claire A Martin, Peter Lau, Riyaben Patel, Julie Lorent, David Papadopoli, Anna Trigos, Teresa Ward, Aparna D Rao, Emily J Lelliott, Karen E Sheppard, David Goode, Rodney J Hicks, Tony Tiganis, Kaylene J Simpson, Ola Larsson
Despite the success of therapies targeting oncogenes in cancer, clinical outcomes are limited by residual disease that ultimately ..
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis
Eric P Kusnadi, Anna S Trigos, Carleen Cullinane, David L Goode, Ola Larsson, Jennifer R Devlin, Keefe T Chan, David P De Souza, Malcolm J McConville, Grant A McArthur, George Thomas, Elaine Sanij, Gretchen Poortinga, Ross D Hannan, Katherine M Hannan, Jian Kang, Richard B Pearson
Elevated ribosome biogenesis in oncogene-driven cancers is commonly targeted by DNA-damaging cytotoxic drugs. Our previous first-i..
Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells
Lorey K Smith, Tiffany Parmenter, Cathryn M Gould, Piyush B Madhamshettiwar, Karen E Sheppard, Kaylene J Simpson, Grant A McArthur
Identification of mechanisms underlying sensitivity and response to targeted therapies, such as the BRAF inhibitor vemurafenib, is..
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance
Claire A Martin, Carleen Cullinane, Laura Kirby, Shatha Abuhammad, Emily J Lelliott, Kelly Waldeck, Richard J Young, Natalie Brajanovski, Donald P Cameron, Rachael Walker, Elaine Sanij, Gretchen Poortinga, Ross D Hannan, Richard B Pearson, Rodney J Hicks, Grant A McArthur, Karen E Sheppard
Increased CDK4 activity occurs in the majority of melanomas and CDK4/6 inhibitors in combination with BRAF and MEK inhibitors are ..
Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies
Andrew J Colebatch, Leon Di Stefano, Stephen Q Wong, Ross D Hannan, Paul M Waring, Alexander Dobrovic, Grant A McArthur, Anthony T Papenfuss
Most cancer DNA sequencing studies have prioritized recurrent non-synonymous coding mutations in order to identify novel cancer-re..
Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome
Lih Yin Tan, Chris Mintoff, M Zahied Johan, Brenton W Ebert, Clare Fedele, You Fang Zhang, Pacman Szeto, Karen E Sheppard, Grant A McArthur, Erwin Foster-Smith, Andrew Ruszkiewicz, Michael P Brown, Claudine S Bonder, Mark Shackleton, Lisa M Ebert
Tumors can develop a blood supply not only by promoting angiogenesis but also by forming vessel-like structures directly from tumo..